Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Viatris Inc. and CRISPR Therapeutics AG have taken distinct paths in optimizing these costs.

From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a significant increase of over 200% from their 2014 figures. In contrast, CRISPR Therapeutics AG, a smaller player, saw its SG&A expenses grow from around $5 million in 2014 to nearly $76 million in 2023, marking a 1,400% increase.

While Viatris Inc. manages larger absolute costs, CRISPR Therapeutics AG's rapid growth in expenses reflects its aggressive expansion strategy. Understanding these trends offers valuable insights into each company's operational strategies and market positioning.